2012Journal of Cardiovascular Magnetic ResonanceOpen access

Potential value of T1 mapping in cardiac MR assessment of hypertrophic cardiomyopathy and dilated cardiomyopathy patients: preliminary results

Alexis Jacquier, Alexandros Kallifatidis, Franck Thuny, Jean Michel Bartoli, Boris Maurel, G. Moulin

Open full text 0 citations

Abstract

Myocardial fibrosis causes 1) increased stiffness and induces pathological signaling in cardiomyocytes resulting in progressive cardiac failure, 2)impairs mechano-electric coupling of cardiomyocytes and increases the risk of arrhythmias. T1 mapping allow to quantify the total amount of myocardial extracellular volume and to subsequently define the amount of myocardial fibrosis. Quantification of fibrosis in dilated and hypertrophic cardiomyopathies and it's link to delayed myocardial enhancement is unclear. Twelve patients with HCM, 10 with DCM, and 5 controls subjects were prospectively included. All patients underwent cardiac MR with the following sequences (parameters set according to recommendation of the SCMR): 1) cine sequence, 2) Molli sequence (TR/TE=3.0ms/1.5ms; matrix 144x150, thickness:7 mm) acquired before and 5, 7, 9 min after gadolinium injection (DOTAREM, 0,2mmol/kg). 3) Late gadolinium enhanced sequence 10min after injection. T1 values were assessed in blood and in the 6 segments of the mid LV slice. Patient with (+) and without (-) enhancement on LGE were analysed separately. Were calculated: R1, ΔR1, ΔR1 ratio (partition coefficient of Gd, λ). in controls before injection T1 value was 0,98s ±0,05 s in myocardium, and 1,63 s ±0,08 in blood. λ was measured at 0.43±0,03 in normal. In DCM, λ was not significantly different between patient with (0.51±0,04) and without (0.50±0,05) enhancement on LGE (p=0.2). In HCM, λ was significantly different between patient with (0.54±0,08) and without (0.45±0,05) enhancement on LGE (p<0.0001)(figure 1 ). No significant difference was measured in λ value between control and HCM - (p=0.1). Graph showing the λ value from different group. T1 mapping allow for quantification of the total amount of fibrosis in a myocardium. In DCM the distribution of fibrosis might be more diffused compared with HCM. These results have to be confirmed by larger study.

Open-access reader

About this research paper

What this paper is about

Myocardial fibrosis causes 1) increased stiffness and induces pathological signaling in cardiomyocytes resulting in progressive cardiac failure, 2)impairs mechano-electric coupling of cardiomyocytes and increases the risk of arrhythmias. T1 mapping allow to quantify the total amount of myocardial extracellular volume and to subsequently define the amount of myocardial fibrosis. Quantification of fibrosis in dilated and hypertrophic cardiomyopathies and it's link to delayed myocardial enhancement is unclear. Twelve patients with HCM, 10 with DCM, and 5 controls subjects were prospectively included. All patients underwent cardiac MR with the following sequences (parameters set according to recommendation of the SCMR): 1) cine sequence, 2) Molli sequence (TR/TE=3.0ms/1.5ms; matrix 144x150, thickness:7 mm) acquired before and 5, 7, 9 min after gadolinium injection (DOTAREM, 0,2mmol/kg). 3) Late gadolinium enhanced sequence 10min after injection. T1 values were assessed in blood and in the 6 segments of the mid LV slice. Patient with (+) and without (-) enhancement on LGE were analysed separately. Were calculated: R1, ΔR1, ΔR1 ratio (partition coefficient of Gd, λ). in controls before injection T1 value was 0,98s ±0,05 s in myocardium, and 1,63 s ±0,08 in blood. λ was measured at 0.43±0,03 in normal. In DCM, λ was not significantly different between patient with (0.51±0,04) and without (0.50±0,05) enhancement on LGE (p=0.2). In HCM, λ was significantly different between patient with (0.54±0,08) and without (0.45±0,05) enhancement on LGE (p<0.0001)(figure 1 ). No significant difference was measured in λ value between control and HCM - (p=0.1). Graph showing the λ value from different group. T1 mapping allow for quantification of the total amount of fibrosis in a myocardium. In DCM the distribution of fibrosis might be more diffused compared with HCM. These results have to be confirmed by larger study.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Myocardial fibrosis causes 1) increased stiffness and induces pathological signaling in cardiomyocytes resulting in progressive cardiac failure, 2)impairs mechano-electric coupling of cardiomyocytes and increases the risk of arrhythmias. T1 mapping allow to quantify the total amount of myocardial extracellular volume and to subsequently define the amount of myocardial fibrosis. Quantification of fibrosis in dilated and hypertrophic cardiomyopathies and it's link to delayed myocardial enhancement is unclear. Twelve patients with HCM, 10 with DCM, and 5 controls subjects were prospectively included. All patients underwent cardiac MR with the following sequences (parameters set according to recommendation of the SCMR): 1) cine sequence, 2) Molli sequence (TR/TE=3.0ms/1.5ms; matrix 144x150, thickness:7 mm) acquired before and 5, 7, 9 min after gadolinium injection (DOTAREM, 0,2mmol/kg). 3) Late gadolinium enhanced sequence 10min after injection. T1 values were assessed in blood and in the 6 segments of the mid LV slice. Patient with (+) and without (-) enhancement on LGE were analysed separately. Were calculated: R1, ΔR1, ΔR1 ratio (partition coefficient of Gd, λ). in controls before injection T1 value was 0,98s ±0,05 s in myocardium, and 1,63 s ±0,08 in blood. λ was measured at 0.43±0,03 in normal. In DCM, λ was not significantly different between patient with (0.51±0,04) and without (0.50±0,05) enhancement on LGE (p=0.2). In HCM, λ was significantly different between patient with (0.54±0,08) and without (0.45±0,05) enhancement on LGE (p<0.0001)(figure 1 ). No significant difference was measured in λ value between control and HCM - (p=0.1). Graph showing the λ value from different group. T1 mapping allow for quantification of the total amount of fibrosis in a myocardium. In DCM the distribution of fibrosis might be more diffused compared with HCM. These results have to be confirmed by larger study.

Key concepts: Medicine, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Cardiology, Myocardial fibrosis, Internal medicine, Angiology, Fibrosis

Related papers

Back to paper searchBrowse research topicsOriginal source
Potential value of T1 mapping in cardiac MR assessment of hypertrophic cardiomyopathy and dilated cardiomyopathy patients: preliminary results — Research Paper | ScholarLens